DIOSynVax, a clinical-stage biotech company specializing in revolutionary broadly protective vaccines, has appointed Ron Moss as its new CEO based in the US. He succeeds company founder, Professor Jonathan Heeney of Cambridge…
UK: Moss takes up new role as CEO of DIOSynVax based in US
…
…






